期刊文献+

蒲地蓝消炎口服液治疗小儿手足口病的疗效观察 被引量:26

Therapeutic Effects of Pudilan Xiaoyan Oral Liquid on Children with Hand,Foot and Mouth Disease
下载PDF
导出
摘要 目的:观察蒲地蓝消炎口服液治疗小儿手足口病的临床疗效。方法:选择门诊176例手足口病患儿随机分成两组,治疗组130例口服蒲地蓝消炎口服液;对照组46例口服利巴韦林颗粒。结果:两组疗效比较,治疗组显效率(57.5%)、总有效率(92.5%)均明显优于对照组(分别为19.4%,69.4%),差异有统计学意义(P<0.01);两组总病程、口腔溃疡好转时间比较差异有统计学意义(P<0.05);两组总热程、用药后热程、皮疹消退时间比较差异有统计学意义(P<0.01)。结论:蒲地蓝消炎口服液治疗手足口病疗效显著,预后良好,能缩短疗程,未见明显不良反应。 Objective: To evaluate the therapeutic effects of Pudilan Xiaoyan oral liquid in children with hand, foot and mouth disease (HFMD). Methods: One hundred and seventy-six patients with HFMD in our out-patient department were randomly divided into two groups. One hundred and thirty patients in the therapeutic group were treated with Pudilan Xiaoyan oral liquid; 46 patients in the control group were treated with oral ribavirin. Results: The marked effect rate and the total effective rate of the therapeutic group were significantly higher than those of the control group ( P 〈 0.01 ). The difference in disappearing of main symptom and sign, total course of disease, oral ulcer improvement time was significant (P 〈 0.05 ) between the therapeutic group and the control group. There was a significant difference in total length of fever time, length of fever time after treatment and deflorescence time between the therapeutic group and the control group (P 〈 0.01 ). Conclusions: Pudilan Xiaoyan oral liquid has a good therapeutic effect in children with HFMD, and shortened duration of HFMD with no complications and adverse reactions.
出处 《儿科药学杂志》 CAS 2009年第5期32-34,共3页 Journal of Pediatric Pharmacy
关键词 手足口病 蒲地蓝消炎口服液 利巴韦林 儿童 Hand, foot and mouth disease Pudilan Xiaoyan oral liquid Ribavirin Children
  • 相关文献

参考文献4

二级参考文献14

  • 1李红艳,欧国萍,邓智怀.HPLC测定解热清肺糖浆中黄芩苷的含量[J].中成药,2004,26(10). 被引量:1
  • 2蒋荣珍,陈琨凤,黎强.HPLC法测定感冒止咳糖浆中连翘苷的含量[J].广西中医学院学报,2006,9(2):69-71. 被引量:5
  • 3Chen SC, Chang HL, Yan TR, et al. An eight-year study of epidemiologlc features of enterovirus 71 infection in Taiwan[ J]. Am J Trop Med Hyg,2007,77( 1 ) :188 -191.
  • 4Ooi MH, Wong SC, Podin y, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study [ J ]. Clin Infect Dis, 2007,44 ( 5 ) :646 - 656.
  • 5Tu PV,Thao NT, Perera D, et al. Epidemiologie and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005[ J]. Emerg Infect Dis,2007,13 (11) :1733 - 1741.
  • 6中华人民共和国卫生部.肠道病毒(EV71)感染诊疗指南(2008年版)[S],2008.
  • 7Chen TC, Chen GW, Hsiung CA, et al. Combining multiplex reverse transcription-PCR and a diagnostic microarray to detect and differentiate enterovirus 71 and coxsackie virus A16[J]. J Clin Microbiol ,2006 ,44 (6) :2212 -2219.
  • 8Legay F,Leveque N, Gacouin A, et al. Fatal coxsackie virus A-16 pneumonitis in adult [ J]. Emerg Infect Dis,2007,13 (7) :1084 - 1086.
  • 9香港科技大学生物技术研究所.中药研究与开发综述[M].北京:科学出版社,2000.105.
  • 10中华人民共和国药典委员会.中华人民共和国药典(2005年版一部)[M].化学工业出版社,2000.附录41-45.

共引文献90

同被引文献205

引证文献26

二级引证文献133

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部